{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "LOINC|ACTIVE" in comments (approximate match)
Status:
US Previously Marketed
Source:
CHYMODIACTIN by DISCURE MEDICAL, LLC
(1982)
Source URL:
First approved in 1982
Source:
CHYMODIACTIN by DISCURE MEDICAL, LLC
Source URL:
Class:
PROTEIN
Status:
First approved in 1955
Class:
PROTEIN
Status:
First approved in 1953
Class:
PROTEIN
Status:
US Previously Marketed
First approved in 1940
Class:
PROTEIN
Status:
US Previously Marketed
First marketed in 1921
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03169660: Phase 4 Interventional Completed Exudative Age-related Macular Degeneration
(2015)
Source URL:
First approved in 2023
Source:
DR.K CELL REPAIR GENIC AMPOULE by Noblesse Korea Co., Ltd.
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
M020
(2022)
Source URL:
First approved in 2022
Source:
M020
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
BLA125659
(2021)
Source URL:
First approved in 2021
Source:
BLA125659
Source URL:
Class:
PROTEIN
